Landos Biopharma, Inc.
DelistedCIK 1785345fmd_071SYY0RN04F24XRBPPRTXJG87Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Mar 31, 2024, 17 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | 0 | 18 | – | – |
| Net interest income | 1 | 0 | 1 | 1 |
| Research and development | 25 | 42 | 26 | 12 |
| Total operating expenses | 31 | 57 | 41 | 23 |
| Operating income | (31) | (39) | (41) | (23) |
| Other non-operating income (expense) | – | – | – | 1 |
| Income before taxes | (30) | (38) | (39) | (22) |
| Net income | (30) | (38) | (39) | (22) |